China's LAA closure devices market to grow at 5% CAGR through 2033

The competitive landscape is expected to fuel an increase in research and development investments.

China’s left atrial appendage (LAA) closure devices market is projected to rise at a compound annual growth rate (CAGR) of 5% through 2033, on the back of a rising prevalence of atrial fibrillation (AFib) and increased stroke prevention awareness, said GlobalData.

A recent key development is the regulatory approval of AtriCure's AtriClip system by the country’s National Medical Products Administration (NMPA).

According to the report, AtriCure holds a 35% share of the Asia Pacific (APAC) structural heart occlusion device market.

Jyoti Sharma, medical devices analyst at GlobalData, said that this is likely to encourage competitors to enhance their product offerings and strategies.

“This competitive landscape is expected to drive increased investment in research and development,” she said.